Sentaur Biosciences

Pioneering Precision Therapeutics for Senescence Driven Diseases

Health Tech & Life Sciences
Non Active, Mar 2024 ceased to operate
Seed Yavne, Israel Founded 2018
LinkedIn
Last updated 2026-06-18
Total raised
Last: 2023-07
Stage
Seed
Founded
2018
Headcount
3
HQ
Yavne, Israel
Sector
Health Tech & Life Sciences

About

Sentaur Bio is a biotech company with a focus on senescence biology that discovers and develops breakthrough treatments for debilitating age-related diseases.

Sentaur’s library of distinct senescent cell surface proteins discovered by high throughput proteomic analysis, was licensed from the laboratory of Prof. Valery Krizhanovsky, an Associate Professor at the Weizmann Institute of Science and a world-renowned expert in senescence. By leveraging its powerful library platform of distinct cell surface proteins, Sentaur’s mission is to treat diseases involving senescent cells burden, with primary focus in oncology and in the future debilitating age-related diseases.

The company also aims to leverage its platform to continue discovering and developing surface markers of senescence by strategic partnering.

Funding history · 3 rounds · — total

2023-07
Undisclosed
2021-12
Undisclosed
2018-06
Undisclosed

Q&A

What is Sentaur Biosciences' primary focus?
Sentaur Biosciences is a biotech company focused on senescence biology, discovering and developing treatments for age-related diseases, with a primary focus on oncology.
When was Sentaur Biosciences founded?
Sentaur Biosciences was founded in March 2018.
What is the current status of Sentaur Biosciences?
Sentaur Biosciences is currently inactive, having ceased to operate in March 2024.
How many employees does Sentaur Biosciences have?
Sentaur Biosciences has 1-10 employees.
Who is a key founder of Sentaur Biosciences?
Valery Krizhanovsky is a founder of Sentaur Biosciences.
From whom did Sentaur Biosciences license its library of senescent cell surface proteins?
Sentaur Biosciences licensed its library of distinct senescent cell surface proteins from the laboratory of Prof. Valery Krizhanovsky at the Weizmann Institute of Science.
When was Sentaur Biosciences' most recent funding round?
Sentaur Biosciences' most recent funding round occurred in July 2023, with M Ventures participating.
Which investor has participated in multiple funding rounds for Sentaur Biosciences?
M Ventures has participated in multiple funding rounds for Sentaur Biosciences, including in June 2018, December 2021, and July 2023.

Team · 1

Founder · Founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Tags

oncologyantibodiesbiotechnologycellsimmunologyprecision-medicine
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/88396417

Identifiers & details

Former namesEXPLORE BIO 3
Founded2018-3
Employees (exact)3
Status reasonNon Active, Mar 2024 ceased to operate